Apis Capital Advisors LLC Boosts Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Apis Capital Advisors LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 19.5% in the 4th quarter, HoldingsChannel reports. The firm owned 196,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 32,000 shares during the period. ANI Pharmaceuticals comprises approximately 2.7% of Apis Capital Advisors LLC’s holdings, making the stock its 14th largest position. Apis Capital Advisors LLC’s holdings in ANI Pharmaceuticals were worth $15,472,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the first quarter worth about $28,000. Hantz Financial Services Inc. raised its holdings in ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals during the fourth quarter worth about $48,000. State of Wyoming purchased a new position in ANI Pharmaceuticals during the second quarter worth about $50,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in ANI Pharmaceuticals by 30.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock worth $86,000 after purchasing an additional 253 shares in the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on ANIP. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

Insiders Place Their Bets

In other news, CFO Stephen P. Carey sold 3,312 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.00, for a total value of $264,960.00. Following the sale, the chief financial officer directly owned 180,393 shares in the company, valued at $14,431,440. This represents a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Thomas Andrew Rowland sold 459 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total transaction of $36,357.39. Following the completion of the sale, the senior vice president owned 38,271 shares in the company, valued at $3,031,445.91. This represents a 1.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 79,016 shares of company stock valued at $6,195,991. Corporate insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Trading Down 3.0%

Shares of ANIP opened at $80.52 on Thursday. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The firm’s 50-day moving average is $80.12 and its two-hundred day moving average is $79.37. ANI Pharmaceuticals, Inc. has a twelve month low of $62.60 and a twelve month high of $99.50. The firm has a market capitalization of $1.83 billion, a P/E ratio of 20.38 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period in the prior year, the business posted $1.70 earnings per share. The firm’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.